We are live on ! Find out more
AGRX

Agile Therapeutics
AGRX

Delisted

AGRX was delisted on the 25th of March, 2024.

Back to rankings

17 hedge funds and large institutions have $355K invested in Agile Therapeutics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

6% more funds holding

Funds holding: 16 → 17 (+1)

17% less capital invested

Capital invested by funds: $426K → $355K (-$70.6K)

60% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 5

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
17
Holders Change
+1
Holders Change %
+6.25%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
4
Increased
2
Reduced
5
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$33.9K
2
Citadel Advisors
Citadel Advisors
Florida
+$31.6K
3
JP Morgan Chase
JP Morgan Chase
New York
+$8.52K
4
Wells Fargo
Wells Fargo
California
+$17
5
Comerica Bank
Comerica Bank
Texas
+$10

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$59.1K
2
IA
Investor AB
Sweden
-$5.17K
3
TRCT
Tower Research Capital (TRC)
New York
-$1.28K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$1.24K
5
UBS Group
UBS Group
Switzerland
-$71
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$235K -$59.1K -24,000 -20%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$33.2K +$33.9K +13,790 New
Citadel Advisors
3
Citadel Advisors
Florida
$30.9K +$31.6K +12,825 New
State Street
4
State Street
Massachusetts
$26.1K – – –
BlackRock
5
BlackRock
New York
$14.5K -$52 -21 -0.3%
JP Morgan Chase
6
JP Morgan Chase
New York
$8.36K +$8.52K +3,464 +69,280%
TRCT
7
Tower Research Capital (TRC)
New York
$5.26K -$1.28K -521 -19%
Royal Bank of Canada
8
Royal Bank of Canada
Ontario, Canada
$1K -$1.24K -504 -66%
Citigroup
9
Citigroup
New York
$436 – – –
Morgan Stanley
10
Morgan Stanley
New York
$108 – – –
Wells Fargo
11
Wells Fargo
California
$34 +$17 +7 +100%
CPG
12
Cornerstone Planning Group
New Jersey
$24 – – –
Group One Trading
13
Group One Trading
Illinois
$24 – – –
Osaic Holdings
14
Osaic Holdings
Arizona
$11 -$30 -12 -71%
Comerica Bank
15
Comerica Bank
Texas
$10 +$10 +4 New
Fidelity Investments
16
Fidelity Investments
Massachusetts
$2 +$2 +1 New
IA
17
Investor AB
Sweden
– -$5.17K -1,754 Closed
UBS Group
18
UBS Group
Switzerland
– -$71 -24 Closed
RMA
19
Roffman Miller Associates
Pennsylvania
– -$3 -1 Closed

AGRX Hedge Fund Activity: Q3 2023 in Review

17 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q3 2023, worth a combined $355K — down 17% from $426K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new AGRX positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 5 trimmed.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $33.9K. The largest seller was Armistice Capital, cutting an estimated $59.1K.

  • 17 institutional investors held Agile Therapeutics (AGRX) as of Q3 2023, up from 16 in Q2 2023.
  • Funds reported $355K of Agile Therapeutics stock for Q3 2023, down 17% quarter-over-quarter.
  • 4 funds opened new Agile Therapeutics positions in Q3 2023 and 3 closed out, a net change of +1 holder.
  • The largest Agile Therapeutics buyer in Q3 2023 was Geode Capital Management, an estimated $33.9K added.
  • The largest Agile Therapeutics seller in Q3 2023 was Armistice Capital, an estimated $59.1K sold.

Based on aggregated 13F filings for Q3 2023.